Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia, Proskorovsky et al. Adv Ther (2019);36(8):2147-2160. doi:10.1007/s12325-019-00991-w

Adv Ther. 2020 Feb;37(2):955-957. doi: 10.1007/s12325-019-01168-1. Epub 2019 Dec 14.

Authors

Jinlin Song¹, Wei Gao², Jipan Xie¹, Simran Tiwana³

Affiliations

¹ Analysis Group, Inc., Los Angeles, CA, USA.
² Analysis Group, Inc., Boston, MA, USA. [email protected].
³ Amgen Inc., Thousand Oaks, CA, USA.

No abstract available

Publication types

Letter
Comment

MeSH terms

Acute Disease
Antibodies, Bispecific*
Humans
Inotuzumab Ozogamicin
Precursor Cell Lymphoblastic Leukemia-Lymphoma*

Substances

Antibodies, Bispecific
blinatumomab
Inotuzumab Ozogamicin